BR112015019339A2 - Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico - Google Patents
Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênicoInfo
- Publication number
- BR112015019339A2 BR112015019339A2 BR112015019339A BR112015019339A BR112015019339A2 BR 112015019339 A2 BR112015019339 A2 BR 112015019339A2 BR 112015019339 A BR112015019339 A BR 112015019339A BR 112015019339 A BR112015019339 A BR 112015019339A BR 112015019339 A2 BR112015019339 A2 BR 112015019339A2
- Authority
- BR
- Brazil
- Prior art keywords
- glycosylated
- composition
- epithelial cells
- mammary gland
- human mammal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/102—Caprine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Abstract
ANTICORPO GLICOSILADO, COMPOSIÇÃO, MÉTODO, CÉLULAS EPITELIAIS DE GLÂNDULA MAMÁRIA, MAMÍFERO NÃO HUMANO TRANSGÊNICO, E, USO DO ANTICORPO. Em um aspecto, a descrição refere-se a anticorpos com padrões de glicosilação alterados, métodos de produção de ditos anticorpos, e métodos de uso dos mesmos. Em algumas modalidades, o anticorpo é cetuximab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361764446P | 2013-02-13 | 2013-02-13 | |
PCT/IB2014/000867 WO2014125382A2 (en) | 2013-02-13 | 2014-02-13 | Cetuximab with modified glycosylation and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015019339A2 true BR112015019339A2 (pt) | 2017-08-22 |
Family
ID=50980328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015019339A BR112015019339A2 (pt) | 2013-02-13 | 2014-02-13 | Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico |
Country Status (13)
Country | Link |
---|---|
US (1) | US20160002330A1 (pt) |
EP (1) | EP2956484B1 (pt) |
JP (1) | JP2016513105A (pt) |
KR (1) | KR20150145225A (pt) |
CN (1) | CN105358577A (pt) |
AR (1) | AR094779A1 (pt) |
AU (1) | AU2014217569B2 (pt) |
BR (1) | BR112015019339A2 (pt) |
CA (1) | CA2900915A1 (pt) |
IL (1) | IL240442A0 (pt) |
MX (1) | MX2015010429A (pt) |
TW (1) | TW201444871A (pt) |
WO (1) | WO2014125382A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3834851A1 (en) | 2010-12-30 | 2021-06-16 | Laboratoire Français du Fractionnement et des Biotechnologies | Glycols as pathogen inactive agents |
EP2956480B1 (en) | 2013-02-13 | 2019-09-04 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
TW201509432A (zh) | 2013-07-05 | 2015-03-16 | Lab Francais Du Fractionnement | 親和層析基質 |
US10927384B2 (en) | 2014-04-09 | 2021-02-23 | Dna Twopointo Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
CA3001312A1 (en) | 2015-10-08 | 2017-04-13 | Dna2.0, Inc. | Dna vectors, transposons and transposases for eukaryotic genome modification |
JP2019508380A (ja) * | 2016-01-10 | 2019-03-28 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Egfrに対するグリコシル化キメラ抗体での癌の処置のための改善された安全性 |
CN109415441B (zh) * | 2016-05-24 | 2023-04-07 | 英斯梅德股份有限公司 | 抗体及其制备方法 |
KR102376545B1 (ko) * | 2017-08-01 | 2022-03-21 | 삼성디스플레이 주식회사 | 플렉시블 디스플레이 윈도우 |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
KR20050000558A (ko) * | 2002-05-17 | 2005-01-05 | 헤마테크, 엘엘씨 | 인간 항체를 제조할 수 있는 트랜스제닉 유제동물 |
JP2006507839A (ja) * | 2002-11-27 | 2006-03-09 | ジーティーシー バイオセラピューティックス インコーポレイテッド | 乳中に安定して産生される改変抗体およびその製造方法 |
CA2450289A1 (en) * | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
WO2005111627A2 (en) | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
KR20080068089A (ko) | 2005-10-21 | 2008-07-22 | 지티씨바이오쎄라퓨틱스,인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법 |
FR2901707B1 (fr) * | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
ES2620261T3 (es) * | 2006-09-10 | 2017-06-28 | Glycotope Gmbh | Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos |
WO2008101177A2 (en) * | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
KR20110119702A (ko) * | 2009-01-22 | 2011-11-02 | 모멘타 파머슈티컬스 인코포레이티드 | Cho 세포에서 유도된 글리코단백질 생성물에서의 갈락토오스-알파-1,3-갈락토오스-함유 n-글리칸 |
ES2605677T3 (es) * | 2009-11-11 | 2017-03-15 | Momenta Pharmaceuticals, Inc. | Glucosiltransferasa de hámster chino y métodos relacionados |
-
2014
- 2014-02-13 US US14/767,089 patent/US20160002330A1/en not_active Abandoned
- 2014-02-13 CN CN201480018266.7A patent/CN105358577A/zh active Pending
- 2014-02-13 CA CA2900915A patent/CA2900915A1/en not_active Abandoned
- 2014-02-13 EP EP14732006.3A patent/EP2956484B1/en not_active Not-in-force
- 2014-02-13 KR KR1020157024950A patent/KR20150145225A/ko not_active Application Discontinuation
- 2014-02-13 WO PCT/IB2014/000867 patent/WO2014125382A2/en active Application Filing
- 2014-02-13 AR ARP140100458A patent/AR094779A1/es unknown
- 2014-02-13 AU AU2014217569A patent/AU2014217569B2/en not_active Ceased
- 2014-02-13 TW TW103104778A patent/TW201444871A/zh unknown
- 2014-02-13 BR BR112015019339A patent/BR112015019339A2/pt not_active Application Discontinuation
- 2014-02-13 MX MX2015010429A patent/MX2015010429A/es unknown
- 2014-02-13 JP JP2015557534A patent/JP2016513105A/ja active Pending
-
2015
- 2015-08-09 IL IL240442A patent/IL240442A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2956484B1 (en) | 2018-11-14 |
WO2014125382A2 (en) | 2014-08-21 |
WO2014125382A3 (en) | 2014-11-06 |
IL240442A0 (en) | 2015-09-24 |
JP2016513105A (ja) | 2016-05-12 |
AU2014217569A1 (en) | 2015-08-27 |
CA2900915A1 (en) | 2014-08-21 |
MX2015010429A (es) | 2016-05-16 |
AR094779A1 (es) | 2015-08-26 |
KR20150145225A (ko) | 2015-12-29 |
AU2014217569B2 (en) | 2018-10-25 |
EP2956484A2 (en) | 2015-12-23 |
CN105358577A (zh) | 2016-02-24 |
US20160002330A1 (en) | 2016-01-07 |
TW201444871A (zh) | 2014-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015019339A2 (pt) | Anticorpo glicosilado, composição, método, população de anticorpos glicosilados, células epiteliais de glândula mamária, e, mamífero não humano transgênico | |
BR112015019341A2 (pt) | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal | |
BR112015019343A2 (pt) | Anticorpo anti-her2, composição, método para produção de uma população de anticorpos, células epiteliais das glândulas mamárias, e, mamífero não humano transgênico | |
BR112015019348A2 (pt) | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária | |
CR20150405A (es) | Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios | |
MX2015009742A (es) | Metodo y dispositivo para el analisis de optimizacion de la forma. | |
BR112015025709A2 (pt) | monoterapia com gla para uso em tratamento de câncer | |
CO6990666A2 (es) | Proteinas que pueden unirse a la il-1 | |
EA201691321A1 (ru) | Антитела и способы их применения | |
EA201991332A1 (ru) | Строительная панель, имеющая повышенную прочность фиксации, и способ изготовления данной панели | |
DK3041949T3 (da) | Celler, der producerer fc-holdige molekyler med modificerede glycosyleringsmønstre, og fremgangsmåder og anvendelser deraf | |
FR2979641B1 (fr) | Bandeau de securite et document qui en est pourvu | |
TR201818993T4 (tr) | Saçın kabarıklığının ve parlaklığının değerlendirilmesi için aygıt. | |
PE20160465A1 (es) | Panel de yeso producido mediante una alta relacion de agua con respecto a estuco | |
PE20160636A1 (es) | Productos de yeso que comprenden gel de silice | |
BR112015020853A2 (pt) | reator combustor a vácuo de combustíveis mistos, reator combustor de vórtice triplo e método para queima eficiente de combustíveis mistos em um reator combustor a vácuo de triplo vórtice. | |
BR112016014804A2 (pt) | Método para produzir heparina, mamífero não humano transgênico, células epiteliais mamárias, heparina, e, composição | |
GB201016616D0 (en) | Method and system for determining characteristics of an embryo and uses thereof | |
TWD161419S (zh) | 針盤 | |
GB2522584A (en) | Managing performance policies based on workload scalability | |
TR201910501T4 (tr) | Bir numune alımının birbirine karıştırılmayacak şekilde uygulanması için numune alım metodu. | |
EA201391513A1 (ru) | Моделирование потока в пористой среде с переменной точностью | |
Acquafredda et al. | SEM-EDS and XRF characterization of obsidian bladelets from Portonovo (AN) to identify raw material provenance. | |
ES2525768B1 (es) | Procedimiento para la producción de proteínas recombinantes glicosiladas. | |
FR2981760B1 (fr) | Seismic source with positive reflection plate and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |